Journal of the American Society of Nephrology
2008 JASN IMPACT FACTOR 7.505 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Longenecker, J. C.
Right arrow Articles by Klag, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Longenecker, J. C.
Right arrow Articles by Klag, M. J.
J Am Soc Nephrol 13:1918-1927, 2002
© 2002 American Society of Nephrology

Traditional Cardiovascular Disease Risk Factors in Dialysis Patients Compared with the General Population: The CHOICE Study

J. Craig Longenecker*, Josef Coresh*, Neil R. Powe*, Andrew S. Levey{dagger}, Nancy E. Fink*, Alice Martin{dagger} and Michael J. Klag*

*Johns Hopkins University, Baltimore, Maryland; and {dagger}New England Medical Center, Boston, Massachusetts.

Correspondence to Dr. J. Craig Longenecker, Johns Hopkins University School of Medicine, Suite 2-637, 2024 E Monument Street, Baltimore, MD 21205. Phone: 410-614-6928; Fax: 410-955-0476; E-mail: jlongene{at}jhsph.edu

ABSTRACT. Although atherosclerotic cardiovascular disease (ASCVD) risk in end-stage renal disease (ESRD) is 5 to 30 times that of the general population, few data exist comparing ASCVD risk factors among new dialysis patients to the general population. This cross-sectional study of 1041 dialysis patients describes the prevalence of ASCVD risk factors at the beginning of ESRD compared with estimates of ASCVD risk factors in the adult US population derived from the Third National Health and Nutrition Examination (NHANES III). CHOICE Study participants had a high prevalence of diabetes (54%), hypertension (96%), left ventricular hypertrophy by electrocardiogram (EKG) criteria (22%), low physical activity (80%), hypertriglyceridemia (36%), and low HDL cholesterol (33%). CHOICE participants were more likely to be older, black, and male than NHANES III participants. After adjustment for age, race, gender, and ASCVD (defined as myocardial infarction, revascularization procedure, stroke, carotid endarterectomy, and amputation in CHOICE; and as myocardial infarction and stroke in NHANES III), the prevalence of diabetes, hypertension, left ventricular hypertrophy by EKG, low physical activity, low HDL cholesterol, and hypertriglyceridemia were still more common in CHOICE participants. Smoking, obesity, hypercholesterolemia, and high LDL cholesterol, however, were less common in CHOICE than NHANES III participants. The projected 5-yr ASCVD risk based on the Framingham Risk Equation among those older than 40 yr without ASCVD was higher in CHOICE Study participants (13%) than in the NHANES III participants (6%). In summary, many ASCVD risk factors are more prevalent in ESRD than in the general population and may explain some, but probably not all, of the increased ASCVD risk in ESRD.




This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
M. Cozzolino, M. L. Biondi, A. Galassi, O. Turri, D. Brancaccio, and M. Gallieni
Matrix metalloproteinase-1 and matrix metalloproteinase-3 gene promoter polymorphisms are associated with mortality in haemodialysis patients
Nephrol. Dial. Transplant., July 1, 2009; 24(7): 2207 - 2212.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
A Power, N Duncan, and C Goodlad
Management of the dialysis patient for the hospital physician
Postgrad. Med. J., July 1, 2009; 85(1005): 376 - 381.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
P. Meier, D. Golshayan, E. Blanc, M. Pascual, and M. Burnier
Oxidized LDL Modulates Apoptosis of Regulatory T Cells in Patients with ESRD
J. Am. Soc. Nephrol., June 1, 2009; 20(6): 1368 - 1384.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
R. Perez-Garcia, A. Martin-Malo, J. Fort, X. Cuevas, F. Llados, J. Lozano, F. Garcia, and on behalf of all Investigators from the ANSWER stu
Baseline characteristics of an incident haemodialysis population in Spain: results from ANSWER--a multicentre, prospective, observational cohort study
Nephrol. Dial. Transplant., February 1, 2009; 24(2): 578 - 588.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
R. de Mutsert, D. C. Grootendorst, J. Axelsson, E. W. Boeschoten, R. T. Krediet, F. W. Dekker, and the NECOSAD Study Group
Excess mortality due to interaction between protein-energy wasting, inflammation and cardiovascular disease in chronic dialysis patients
Nephrol. Dial. Transplant., September 1, 2008; 23(9): 2957 - 2964.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
M. Svensson, E. B. Schmidt, K. A. Jorgensen, and J. H. Christensen
The effect of n-3 fatty acids on lipids and lipoproteins in patients treated with chronic haemodialysis: a randomized placebo-controlled intervention study
Nephrol. Dial. Transplant., September 1, 2008; 23(9): 2918 - 2924.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
O. M. Gutierrez, H. Tamez, I. Bhan, J. Zazra, M. Tonelli, M. Wolf, J. L. Januzzi, Y. Chang, and R. Thadhani
N-terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Concentrations in Hemodialysis Patients: Prognostic Value of Baseline and Follow-up Measurements
Clin. Chem., August 1, 2008; 54(8): 1339 - 1348.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
B. Kiberd and R. Panek
Cardiovascular Outcomes in the Outpatient Kidney Transplant Clinic: The Framingham Risk Score Revisited
Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 822 - 828.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
P. Raggi and M. Kleerekoper
Contribution of Bone and Mineral Abnormalities to Cardiovascular Disease in Patients with Chronic Kidney Disease
Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 836 - 843.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
R. L. Jamison, P. Hartigan, J. S. Kaufman, D. S. Goldfarb, S. R. Warren, P. D. Guarino, J. M. Gaziano, and For the Veterans Affairs Site Investigators
Effect of Homocysteine Lowering on Mortality and Vascular Disease in Advanced Chronic Kidney Disease and End-stage Renal Disease: A Randomized Controlled Trial
JAMA, September 12, 2007; 298(10): 1163 - 1170.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
R. Gupta, L. C. Plantinga, J. Coresh, and N. R. Powe
Statin Use and Sepsis in Patients With Chronic Kidney Disease--Reply
JAMA, July 18, 2007; 298(3): 284 - 285.
[Full Text] [PDF]

Home page
 Arch Intern MedHome page
M. C. Foster, S.-J. Hwang, M. G. Larson, N. I. Parikh, J. B. Meigs, R. S. Vasan, T. J. Wang, D. Levy, and C. S. Fox
Cross-Classification of Microalbuminuria and Reduced Glomerular Filtration Rate: Associations Between Cardiovascular Disease Risk Factors and Clinical Outcomes
Arch Intern Med, July 9, 2007; 167(13): 1386 - 1392.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
J. Nogueira and M. Weir
The Unique Character of Cardiovascular Disease in Chronic Kidney Disease and Its Implications for Treatment with Lipid-Lowering Drugs
Clin. J. Am. Soc. Nephrol., July 1, 2007; 2(4): 766 - 785.
[Abstract] [Full Text] [PDF]

Home page
 pdiHome page
A. Y.-M. Wang
CARDIOVASCULAR RISK FACTORS IN PERITONEAL DIALYSIS PATIENTS REVISITED
Perit. Dial. Int., June 1, 2007; 27(Supplement_2): S223 - S227.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
S. Bro, C. J. Binder, J. L. Witztum, K. Olgaard, and L. B. Nielsen
Inhibition of the Renin-Angiotensin System Abolishes the Proatherogenic Effect of Uremia in Apolipoprotein E-Deficient Mice
Arterioscler Thromb Vasc Biol, May 1, 2007; 27(5): 1080 - 1086.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
B. C.H. Kwan, F. Kronenberg, S. Beddhu, and A. K. Cheung
Lipoprotein Metabolism and Lipid Management in Chronic Kidney Disease
J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1246 - 1261.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
J. Portoles, J. M. Lopez-Gomez, P. Aljama, and on behalf of the MAR Study Group
A prospective multicentre study of the role of anaemia as a risk factor in haemodialysis patients: the MAR Study
Nephrol. Dial. Transplant., February 1, 2007; 22(2): 500 - 507.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
Y. Liu, Y. Berthier-Schaad, L. Plantinga, N. E. Fink, R. P. Tracy, W. H. Kao, M. J. Klag, M. W. Smith, and J. Coresh
Functional Variants in the Lymphotoxin-{alpha} Gene Predict Cardiovascular Disease in Dialysis Patients
J. Am. Soc. Nephrol., November 1, 2006; 17(11): 3158 - 3166.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
S. Goncalves, R. Pecoits-Filho, S. Perreto, S. H. Barberato, A. E. M. Stinghen, E. G. A. Lima, R. Fuerbringer, S. M. Sauthier, and M. C. Riella
Associations between renal function, volume status and endotoxaemia in chronic kidney disease patients
Nephrol. Dial. Transplant., October 1, 2006; 21(10): 2788 - 2794.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
N. I. Parikh, S.-J. Hwang, M. G. Larson, J. B. Meigs, D. Levy, and C. S. Fox
Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control.
Arch Intern Med, September 25, 2006; 166(17): 1884 - 1891.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
L. E. Boulware, Y. Liu, N. E. Fink, J. Coresh, D. E. Ford, M. J. Klag, and N. R. Powe
Temporal Relation among Depression Symptoms, Cardiovascular Disease Events, and Mortality in End-Stage Renal Disease: Contribution of Reverse Causality
Clin. J. Am. Soc. Nephrol., May 1, 2006; 1(3): 496 - 504.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
B. Bayes, M. C. Pastor, J. Bonal, A. Foraster, and R. Romero
Oxidative stress, inflammation and cardiovascular mortality in haemodialysis--role of seniority and intravenous ferrotherapy: analysis at 4 years of follow-up
Nephrol. Dial. Transplant., April 1, 2006; 21(4): 984 - 990.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
S. Bro, R. Borup, C. B. Andersen, F. Moeller, K. Olgaard, and L. B. Nielsen
Uremia-Specific Effects in the Arterial Media During Development of Uremic Atherosclerosis in Apolipoprotein E-Deficient Mice
Arterioscler Thromb Vasc Biol, March 1, 2006; 26(3): 570 - 575.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
Y. Liu, Y. Berthier-Schaad, M. D. Fallin, N. E. Fink, R. P. Tracy, M. J. Klag, M. W. Smith, and J. Coresh
IL-6 Haplotypes, Inflammation, and Risk for Cardiovascular Disease in a Multiethnic Dialysis Cohort
J. Am. Soc. Nephrol., March 1, 2006; 17(3): 863 - 870.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
K. Narkiewicz
Obesity and hypertension--the issue is more complex than we thought
Nephrol. Dial. Transplant., February 1, 2006; 21(2): 264 - 267.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
M. C. Matteucci, E. Wuhl, S. Picca, A. Mastrostefano, G. Rinelli, C. Romano, G. Rizzoni, O. Mehls, G. de Simone, F. Schaefer, et al.
Left Ventricular Geometry in Children with Mild to Moderate Chronic Renal Insufficiency
J. Am. Soc. Nephrol., January 1, 2006; 17(1): 218 - 226.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
V. Menon, T. Greene, A. A. Pereira, X. Wang, G. J. Beck, J. W. Kusek, A. J. Collins, A. S. Levey, and M. J. Sarnak
Glycosylated Hemoglobin and Mortality in Patients with Nondiabetic Chronic Kidney Disease
J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3411 - 3417.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
C. R. Nolan
Strategies for Improving Long-Term Survival in Patients with ESRD
J. Am. Soc. Nephrol., November 1, 2005; 16(11_suppl_2): S120 - S127.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
R. Vanholder, Z. Massy, A. Argiles, G. Spasovski, F. Verbeke, N. Lameire, and for the European Uremic Toxin Work Group (EUTox)
Chronic kidney disease as cause of cardiovascular morbidity and mortality
Nephrol. Dial. Transplant., June 1, 2005; 20(6): 1048 - 1056.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
W. M. McClellan and G. M. Chertow
Beyond Framingham: Cardiovascular Risk Profiling in ESRD
J. Am. Soc. Nephrol., June 1, 2005; 16(6): 1539 - 1541.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
B. C. Astor, J. A. Eustace, N. R. Powe, M. J. Klag, N. E. Fink, J. Coresh, and for the CHOICE Study
Type of Vascular Access and Survival among Incident Hemodialysis Patients: The Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study
J. Am. Soc. Nephrol., May 1, 2005; 16(5): 1449 - 1455.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
S. M. Moe and N. X. Chen
Pathophysiology of Vascular Calcification in Chronic Kidney Disease
Circ. Res., September 17, 2004; 95(6): 560 - 567.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
G. M. Chertow, P. Raggi, S. Chasan-Taber, J. Bommer, H. Holzer, and S. K. Burke
Determinants of progressive vascular calcification in haemodialysis patients
Nephrol. Dial. Transplant., June 1, 2004; 19(6): 1489 - 1496.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
F. Locatelli, A. Covic, C. Chazot, K. Leunissen, J. Luno, and M. Yaqoob
Hypertension and cardiovascular risk assessment in dialysis patients
Nephrol. Dial. Transplant., May 1, 2004; 19(5): 1058 - 1068.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
G. A. Kaysen and J. P. Eiserich
The Role of Oxidative Stress-Altered Lipoprotein Structure and Function and Microinflammation on Cardiovascular Risk in Patients with Minor Renal Dysfunction
J. Am. Soc. Nephrol., March 1, 2004; 15(3): 538 - 548.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
Y. Liu, J. Coresh, J. A. Eustace, J. C. Longenecker, B. Jaar, N. E. Fink, R. P. Tracy, N. R. Powe, and M. J. Klag
Association Between Cholesterol Level and Mortality in Dialysis Patients: Role of Inflammation and Malnutrition
JAMA, January 28, 2004; 291(4): 451 - 459.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
M. J. Sarnak, A. S. Levey, A. C. Schoolwerth, J. Coresh, B. Culleton, L. L. Hamm, P. A. McCullough, B. L. Kasiske, E. Kelepouris, M. J. Klag, et al.
Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention
Hypertension, November 1, 2003; 42(5): 1050 - 1065.
[Full Text] [PDF]

Home page
 CirculationHome page
M. J. Sarnak, A. S. Levey, A. C. Schoolwerth, J. Coresh, B. Culleton, L. L. Hamm, P. A. McCullough, B. L. Kasiske, E. Kelepouris, M. J. Klag, et al.
Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention
Circulation, October 28, 2003; 108(17): 2154 - 2169.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
C. Zoccali, F. Mallamaci, G. Tripepi, F. A. Benedetto, S. Parlongo, S. Cutrupi, D. Iellamo, G. Bonanno, F. Rapisarda, P. Fatuzzo, et al.
Prospective Study of Neuropeptide Y as an Adverse Cardiovascular Risk Factor in End-Stage Renal Disease
J. Am. Soc. Nephrol., October 1, 2003; 14(10): 2611 - 2617.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
S. S. Prichard
Impact of Dyslipidemia in End-Stage Renal Disease
J. Am. Soc. Nephrol., September 1, 2003; 14(90004): S315 - 320.
[Abstract] [Full Text]

Home page
 Journal of Renin-Angiotensin-Aldosterone SystemHome page
D. A Sica and T. W. Gehr
Review: The pharmacokinetics and pharmacodynamics of angiotensin-receptor blockers in end-stage renal disease
Journal of Renin-Angiotensin-Aldosterone System, December 1, 2002; 3(4): 247 - 254.
[Abstract] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673